A citation-based method for searching scientific literature

Jonatan Barrera-Chimal, Ixchel Lima-Posada, George L Bakris, Frederic Jaisser. Nat Rev Nephrol 2022
Times Cited: 10







List of co-cited articles
51 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph,[...]. N Engl J Med 2020
381
60

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Bertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, Stefan D Anker, George L Bakris, Peter Rossing, Amer Joseph, Peter Kolkhof, Christina Nowack, Patrick Schloemer,[...]. N Engl J Med 2021
111
50

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
40

Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
Rajiv Agarwal, Amer Joseph, Stefan D Anker, Gerasimos Filippatos, Peter Rossing, Luis M Ruilope, Bertram Pitt, Peter Kolkhof, Charlie Scott, Robert Lawatscheck,[...]. J Am Soc Nephrol 2022
13
40

Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.
Peter Kolkhof, Elke Hartmann, Alexius Freyberger, Mira Pavkovic, Ilka Mathar, Peter Sandner, Karoline Droebner, Amer Joseph, Jörg Hüser, Frank Eitner. Am J Nephrol 2021
24
40

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
Rajiv Agarwal, Peter Kolkhof, George Bakris, Johann Bauersachs, Hermann Haller, Takashi Wada, Faiez Zannad. Eur Heart J 2021
74
40

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Juliana C N Chan, Adriaan Kooy, Kieran McCafferty, Guntram Schernthaner,[...]. Kidney Int Rep 2021
17
40

Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
Jonatan Barrera-Chimal, Sophie Girerd, Frederic Jaisser. Kidney Int 2019
81
40

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, Rajiv Agarwal, Clare Arnott, George Bakris, Christopher P Cannon, David M Charytan, Robert Edwards, Jose L Górriz,[...]. Eur Heart J 2021
28
30

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Rajiv Agarwal, Gerasimos Filippatos, Bertram Pitt, Stefan D Anker, Peter Rossing, Amer Joseph, Peter Kolkhof, Christina Nowack, Martin Gebel, Luis M Ruilope,[...]. Eur Heart J 2022
32
30

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.
Bertram Pitt, Lars Kober, Piotr Ponikowski, Mihai Gheorghiade, Gerasimos Filippatos, Henry Krum, Christina Nowack, Peter Kolkhof, So-Young Kim, Faiez Zannad. Eur Heart J 2013
283
30

Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.
Lars Bärfacker, Alexander Kuhl, Alexander Hillisch, Rolf Grosser, Santiago Figueroa-Pérez, Heike Heckroth, Adam Nitsche, Jens-Kerim Ergüden, Heike Gielen-Haertwig, Karl-Heinz Schlemmer,[...]. ChemMedChem 2012
142
30

The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling.
Jonatan Barrera-Chimal, Gabriel R Estrela, Sebastian M Lechner, Sébastien Giraud, Soumaya El Moghrabi, Shiem Kaaki, Peter Kolkhof, Thierry Hauet, Frédéric Jaisser. Kidney Int 2018
59
30

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
947
30

Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity.
Jana Grune, Niklas Beyhoff, Elia Smeir, Remigiusz Chudek, Annelie Blumrich, Zsofia Ban, Sarah Brix, Iris R Betz, Michael Schupp, Anna Foryst-Ludwig,[...]. Hypertension 2018
65
30

The mineralocorticoid receptor as a modulator of innate immunity and atherosclerosis.
Charlotte D C C van der Heijden, Jaap Deinum, Leo A B Joosten, Mihai G Netea, Niels P Riksen. Cardiovasc Res 2018
33
20

Mineralocorticoid Receptor and Cardiovascular Disease.
Mathieu Buonafine, Benjamin Bonnard, Frédéric Jaisser. Am J Hypertens 2018
38
20

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.
Jérôme Fagart, Alexander Hillisch, Jessica Huyet, Lars Bärfacker, Michel Fay, Ulrich Pleiss, Elisabeth Pook, Stefan Schäfer, Marie-Edith Rafestin-Oblin, Peter Kolkhof. J Biol Chem 2010
124
20

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.
Peter Rossing, Rajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Aslam Amod, Michel Marre, Amer Joseph, Andrea Lage,[...]. Diabetes Obes Metab 2022
10
20

The incidence and implications of aldosterone breakthrough.
Andrew S Bomback, Philip J Klemmer. Nat Clin Pract Nephrol 2007
272
20

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
George L Bakris, Rajiv Agarwal, Juliana C Chan, Mark E Cooper, Ron T Gansevoort, Hermann Haller, Giuseppe Remuzzi, Peter Rossing, Roland E Schmieder, Christina Nowack,[...]. JAMA 2015
328
20

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
Naveed Sattar, Matthew M Y Lee, Søren L Kristensen, Kelley R H Branch, Stefano Del Prato, Nardev S Khurmi, Carolyn S P Lam, Renato D Lopes, John J V McMurray, Richard E Pratley,[...]. Lancet Diabetes Endocrinol 2021
60
20

Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Peter Kolkhof, Martina Delbeck, Axel Kretschmer, Wolfram Steinke, Elke Hartmann, Lars Bärfacker, Frank Eitner, Barbara Albrecht-Küpper, Stefan Schäfer. J Cardiovasc Pharmacol 2014
170
20

Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.
Radica Z Alicic, Emily J Cox, Joshua J Neumiller, Katherine R Tuttle. Nat Rev Nephrol 2021
27
20

Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Ulrich Kintscher, George L Bakris, Peter Kolkhof. Br J Pharmacol 2022
8
25

Cardiac Tissue Injury and Remodeling Is Dependent Upon MR Regulation of Activation Pathways in Cardiac Tissue Macrophages.
Jimmy Z Shen, James Morgan, Greg H Tesch, Amanda J Rickard, Sophocles Chrissobolis, Grant R Drummond, Peter J Fuller, Morag J Young. Endocrinology 2016
39
20

Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice.
Michael G Usher, Sheng Zhong Duan, Christine Y Ivaschenko, Ryan A Frieler, Stefan Berger, Günther Schütz, Carey N Lumeng, Richard M Mortensen. J Clin Invest 2010
273
20

Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice.
Benjamin Bonnard, Marie Pieronne-Deperrois, Zoubir Djerada, Soumaya Elmoghrabi, Peter Kolkhof, Antoine Ouvrard-Pascaud, Paul Mulder, Frédéric Jaisser, Smail Messaoudi. J Mol Cell Cardiol 2018
19
20

Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study.
Takashi Wada, Masaya Inagaki, Toru Yoshinari, Ryuji Terata, Naoko Totsuka, Miki Gotou, Gaia Hashimoto. Clin Exp Nephrol 2021
20
20

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Gerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Patrick Schloemer, Ingo Tornus, Amer Joseph,[...]. Circulation 2021
80
20

Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE/RAGE axis in a chronic renal failure rat model.
Chun-Cheng Wang, An-Sheng Lee, Shu-Hui Liu, Kuan-Cheng Chang, Ming-Yi Shen, Chiz-Tzung Chang. BMC Nephrol 2019
14
20


Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association.
Janani Rangaswami, Vivek Bhalla, Ian H de Boer, Alexander Staruschenko, Johanna A Sharp, Radhika Rajgopal Singh, Kevin Bryan Lo, Katherine Tuttle, Muthiah Vaduganathan, Hector Ventura,[...]. Circulation 2020
49
20

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
20

Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.
Ralph A DeFronzo, W Brian Reeves, Alaa S Awad. Nat Rev Nephrol 2021
68
20

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, Muhammad Shahzeb Khan, Nikolaus Marx, Carolyn S P Lam, Sven Schnaidt, Anne Pernille Ofstad, Martina Brueckmann, Waheed Jamal,[...]. Circulation 2021
80
20

The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists.
Michele Provenzano, Niels Jongs, Priya Vart, Bergur V Stefánsson, Glenn M Chertow, Anna Maria Langkilde, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström,[...]. Kidney Int Rep 2021
6
33

A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases.
Kitty J Jager, Csaba Kovesdy, Robyn Langham, Mark Rosenberg, Vivekanand Jha, Carmine Zoccali. Kidney Int 2019
92
20

Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
Sadayoshi Ito, Naoki Kashihara, Kenichi Shikata, Masaomi Nangaku, Takashi Wada, Yasuyuki Okuda, Tomoko Sawanobori. Clin J Am Soc Nephrol 2020
47
20

Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
N J Brown, S Nakamura, L Ma, I Nakamura, E Donnert, M Freeman, D E Vaughan, A B Fogo. Kidney Int 2000
217
20

Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
Peter Kolkhof, Frederic Jaisser, So-Young Kim, Gerasimos Filippatos, Christina Nowack, Bertram Pitt. Handb Exp Pharmacol 2017
56
20

11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022.
Boris Draznin, Vanita R Aroda, George Bakris, Gretchen Benson, Florence M Brown, RaShaye Freeman, Jennifer Green, Elbert Huang, Diana Isaacs, Scott Kahan,[...]. Diabetes Care 2022
17
20

Diabetic Kidney Disease: Challenges, Progress, and Possibilities.
Radica Z Alicic, Michele T Rooney, Katherine R Tuttle. Clin J Am Soc Nephrol 2017
729
20

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
Larbi Amazit, Florian Le Billan, Peter Kolkhof, Khadija Lamribet, Say Viengchareun, Michel R Fay, Junaid A Khan, Alexander Hillisch, Marc Lombès, Marie-Edith Rafestin-Oblin,[...]. J Biol Chem 2015
58
20

Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction.
Marianne Lachaux, Jonatan Barrera-Chimal, Lionel Nicol, Isabelle Rémy-Jouet, Sylvanie Renet, Anais Dumesnil, Didier Wecker, Vincent Richard, Peter Kolkhof, Frederic Jaisser,[...]. Diabetes Obes Metab 2018
21
20

Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress.
Raquel González-Blázquez, Beatriz Somoza, Marta Gil-Ortega, Miriam Martín Ramos, David Ramiro-Cortijo, Elena Vega-Martín, Angela Schulz, Luis Miguel Ruilope, Peter Kolkhof, Reinhold Kreutz,[...]. Front Pharmacol 2018
20
20

Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.
Shigeru Shibata, Miki Nagase, Shigetaka Yoshida, Hiroshi Kawachi, Toshiro Fujita. Hypertension 2007
274
20

Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Gerasimos Filippatos, George L Bakris, Bertram Pitt, Rajiv Agarwal, Peter Rossing, Luis M Ruilope, Javed Butler, Carolyn S P Lam, Peter Kolkhof, Luke Roberts,[...]. J Am Coll Cardiol 2021
20
20

Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy.
Jana Grune, Verena Benz, Sarah Brix, Janek Salatzki, Annelie Blumrich, Beata Höft, Robert Klopfleisch, Anna Foryst-Ludwig, Peter Kolkhof, Ulrich Kintscher. J Cardiovasc Pharmacol 2016
42
20

Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease.
Tatsufumi Oka, Yusuke Sakaguchi, Koki Hattori, Yuta Asahina, Sachio Kajimoto, Yohei Doi, Jun-Ya Kaimori, Yoshitaka Isaka. Hypertension 2022
4
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.